Recommended Topic Related To:

Levulan Kerastick

"Aug. 5, 2013 -- Anyone who develops a rash, blister, or some other skin reaction while taking acetaminophen should stop using the drug and seek medical care immediately. The painkiller poses the risk for three rare but potentially fatal skin diso"...

Levulan Kerastick

CLINICAL PHARMACOLOGY

Pharmacology: The metabolism of aminolevulinic acid (ALA) is the first step in the biochemical pathway resulting in heme synthesis. Aminolevulinic acid is not a photosensitizer, but rather a metabolic precursor of protoporphyrin IX (PpIX), which is a photosensitizer. The synthesis of ALA is normally tightly controlled by feedback inhibition of the enzyme, ALA synthetase, presumably by intracellular heme levels. ALA, when provided to the cell, bypasses this control point and results in the accumulation of PpIX, which is converted into heme by ferrochelatase through the addition of iron to the PpIX nucleus.

According to the presumed mechanism of action, photosensitization following application of LEVULAN KERASTICK (aminolevulinic acid) Topical Solution occurs through the metabolic conversion of ALA to PpIX, which accumulates in the skin to which LEVULAN Topical Solution has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using the LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution, plus illumination with the BLU-U® Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for LEVULAN photodynamic therapy (PDT).

Pharmacokinetics: In a human pharmacokinetic study (N=6) using a 128 mg dose of sterile intravenous ALA HCl and oral ALA HCl (equivalent to 100 mg ALA) in which plasma ALA and PpIX were measured, the mean half-life of ALA was 0.70 ± 0.18 h after the oral dose and 0.83 ± 0.05 h after the intravenous dose. The oral bioavailability of ALA was 50-60% with a mean Cmax of 4.65 ± 0.94 μg/mL. PpIX concentrations were low and were detectable only in 42% of the plasma samples. PpIX concentrations in plasma were quite low relative to ALA plasma concentrations, and were below the level of detection (10 ng/mL) after 10 to 12 hours.

ALA does not exhibit fluorescence, while PpIX has ahigh fluorescence yield.

Time-dependent changes in surface fluorescence have been used to determine PpIX accumulation and clearance in actinic keratosis lesions and perilesional skin after application of LEVULAN KERASTICK (aminolevulinic acid) Topical Solution in 12 patients. Peak fluorescence intensity was reached in 11 ± 1 h in actinic keratoses and 12 ± 1 h in perilesional skin. The mean clearance half-life of fluorescence for lesions was 30 ± 10 h and 28 ± 6 h for perilesional skin. The fluorescence in perilesional skin was similar to that in actinic keratoses. Therefore, LEVULAN KERASTICK (aminolevulinic acid) Topical Solution should only be applied to the affected skin.

Clinical Studies: LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution, 20%, plus blue light at 6-10.9 J/cm², has been used to treat actinic keratoses in 232 patients in six clinical trials. Phase 3 studies were two, identically designed, multicenter, two-arm studies using LEVULAN KERASTICK (aminolevulinic acid) for Topical Solution applicators plus illumination from the BLU-U for 1000 seconds (16 min 40 sec) for a nominal exposure of 10 J/cm². Patients were excluded from these studies who had a history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins, photodermatosis, or inherited or acquired coagulation defects. A minimum of 4 and a maximum of 15 clinically typical, discrete, (Grade 1 or 2, see table 2 for definition), target actinic keratosis lesions were identified. Target lesions on the face or on the scalp, but not in both locations in the same patient, received treatment. The patients were randomized to receive treatment either with the LEVULAN KERASTICK (aminolevulinic acid) Topical Solution plus BLU-U or vehicle plus BLU-U. Patients were randomized at a 3 to 1 LEVULAN to vehicle ratio. A total of 243 patients were enrolled in two Phase 3 studies (ALA-018, ALA-019). Lesions were designated as cleared (complete response) if the lesion had completely cleared and adherent scaling plaques of actinic keratoses were no longer evident on the surface of the treated skin when palpated. The percentage of patients in whom 75% or more of treated lesions were cleared, and the percentage of patients in whom 100% of treated lesions were cleared (Complete Responders), for each study at 8 weeks after treatment are shown in Table 1.

TABLE 1 - Patient Responses at Week 8

  ALA-018 ALA-019
LEVULAN Vehicle LEVULAN Vehicle
Patients with >75% of AK Lesions Cleared
Total No. Patients 68/87(78%) 6/29(21%) 71/93(76%) 8/32(25%)
Patients with Face Lesions 57/71(80%) 2/21(10%) 57/67(85%) 7/19(37%)
Patients with Scalp Lesions 11/16(69%) 4/8 (50%) 14/26(54%) 1/13 (8%)
  Complete Responders
Total No.Patients 60/87(69%) 4/29(14%) 59/93(63%) 4/32(13%)
Patients with Face Lesions 49/71(69%) 2/21(10%) 47/67(70%) 4/19(21%)
Patients with Scalp Lesions 11/16(69%) 2/8 (25%) 12/26(46%) 0/13 (0%)

Because clinical studies ALA-018 and ALA-019 had identical protocols, the combined results from the two trials are shown in the following tables. For actinic keratoses with a variety of thicknesses (excluding very thick, Grade 3 actinic keratoses which were not studied in the phase 3 trials), LEVULAN KERASTICK (aminolevulinic acid) Topical Solution plus BLU-U is more effective than vehicle plus BLU-U, but as shown in Table 2, the percentage of lesions with complete responses at 8 weeks after treatment with LEVULAN KERASTICK (aminolevulinic acid) Topical Solution plus blue light illumination was lower for those lesions that were thicker at baseline. Efficacy of LEVULAN KERASTICK (aminolevulinic acid) Topical Solution plus BLU-U on higher grade lesions was not studied in the Phase 3 clinical efficacy trials.

TABLE 2 - Lesions Complete Responses at Week 8 for Different Lesion Grades

  LEVULAN Vehicle
Lesion Grade 1
(Slightly palpable actinic keratoses: better felt than seen)
666/756(88%) 122/302(40%)
Lesion Grade 2
(Moderately thick actinic keratoses: easily seen and felt)
495/632(78%) 52/199 (26%)
Lesion Grade 3
(Very Thick and/or hyperkeratotic actinic keratoses)
0 0

Those patients who were not Complete Responders at week 8 had retreatment of the persistent target lesions at week 8. Among the patients undergoing retreatment, efficacy results seen at 12 weeks after the initial treatment, i.e., at 4 weeks after the second treatment, are shown in Table 3.

TABLE 3 - Complete Responders at Week 12, among Patients Receiving Two Treatments

  LEVULAN Vehicle
Total No. Patients 24/56 (43%) 2/49 (4%)
Patients with Face Lesions 21/40 (53%) 2/31 (6%)
Patients with Scalp Lesions 3/16 (19%) 0/18 (0%)

The efficacy results seen at 12 weeks after treatment, which include the results at 12 weeks for those patients who received a single treatment as well as the results at 12 weeks for those patients who received a second treatment at week 8, are shown in Table 4.

TABLE 4 - Patient Responses at Week 12, among Patients who Received One or Two Treatments

  LEVULAN Vehicle
Patients with >75% of AK Lesions Cleared
Total No. Patients 158/180 (88%) 12/61 (20%)
Patients with Face Lesions 127/138 (92%) 8/40 (20%)
Patients with Scalp Lesions 31/42 (74%) 4/21 (19%)
  Complete Responders
Total No. Patients 129/180 (72%) 7/61 (11%)
Patients with Face Lesions 108/138 (78%) 5/40 (13%)
Patients with Scalp Lesions 21/42 (50%) 2/21 (10%)

Among Complete Responders at week 8, 93%(in study ALA-018) and 83% (in study ALA-019) maintained complete response at week 12. Among patients with scalp lesions, the percentage of patients with 100% of AK lesions having complete response declined from week 8 (55%) to week 12 (50%), because there were more patients with scalp lesions with 100% of AK lesions cleared at week 8 who had a recurrence of a lesion by week 12 than there were patients with scalp lesions who had retreatment of persistent lesions at week 8 and who then achieved 100% of AK lesions cleared by week 12. Patients did not receive follow-up past 12 weeks after the initial treatment.

Patient outcomes recorded in the two Phase 3 trials are depicted in the following flowchart, in which Complete Responders are designated clear. Seven patients in the active treatment arm and three patients in the vehicle treatment arm withdrew or were lost to follow-up, and their outcomes are not included in the flowchart. Three patients in the active treatment arm were treated at baseline but did not return for evaluation until week 12. One patient in the active treatment arm and two in the vehicle treatment arm who were not clear at week 8 did not receive retreatment.

Patient outcomes recorded in the two Phase 3 trials - Illustration

Last reviewed on RxList: 10/8/2008
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


From WebMD